12 patents currently held

2 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Dec 2030. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Dec 2030

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

notable patents all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Methods of Administering Amantadine US 10,646,456

Cited by 34 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.

Ends Jun 2034 · High confidence Also notable

Method of administering amantadine prior to a sleep period US 9,867,793

Cited by 29 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.

Ends Dec 2030 · High confidence Also notable

Methods of Using Amantadine Compositions US 11,077,073

Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.

Ends Aug 2038 · High confidence

Formerly held, still cited

Notable

Composition and Method for Treating Neurological Disease US 8,389,578

The most cited patent in this portfolio, cited by 137 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2028.

now held by Adamas Pharmaceuticals, Inc.

Ends Jan 2028 · High confidence

Also notable

Methods and Compositions for the Treatment of Cns-Related Conditions US 8,058,291

Cited by 84 later US patents, top 10% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.

now held by Adamas Pharmaceuticals, Inc.

Ends Dec 2029 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Aug 20, 2027
The maintenance fee for Methods of Administering Amantadine (US 11,903,908) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
1 fee due Nov 12, 2027
The maintenance fee for Methods of Administering Amantadine (US 10,646,456) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Method of Administering Amantadine Prior to a Sleep Period	6 in force	to Dec 2030
Methods of Using Amantadine Compositions	3 in force	to Aug 2038
Methods of Administering Amantadine	3 in force	to Oct 2034

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,741,343	Method of Administering Amantadine Prior to a Sleep Period In force Term ends Dec 2, 2030 · High confidence	In force	Term ends Dec 2, 2030	High confidence
US 9,867,791	Method of administering amantadine prior to a sleep period In force Term ends Dec 2, 2030 · High confidence	In force	Term ends Dec 2, 2030	High confidence
US 9,867,792	Method of administering amantadine prior to a sleep period In force Ends no later than Dec 2, 2030 · Medium confidence	In force	Ends no later than Dec 2, 2030	Medium confidence
US 9,867,793	Method of administering amantadine prior to a sleep period In force Term ends Dec 2, 2030 · High confidence	In force	Term ends Dec 2, 2030	High confidence
US 9,877,933	Method of administering amantadine prior to a sleep period In force Term ends Dec 2, 2030 · High confidence	In force	Term ends Dec 2, 2030	High confidence
US 11,197,835	Method of administering amantadine prior to a sleep period In force Term ends Dec 2, 2030 · Medium confidence	In force	Term ends Dec 2, 2030	Medium confidence
US 10,646,456	Methods of Administering Amantadine In force Term ends Jun 17, 2034 · High confidence	In force	Term ends Jun 17, 2034	High confidence
US 11,903,908	Methods of Administering Amantadine In force Term ends Jun 17, 2034 · High confidence	In force	Term ends Jun 17, 2034	High confidence
US 10,154,971	Methods of Administering Amantadine In force Term ends Oct 4, 2034 · High confidence	In force	Term ends Oct 4, 2034	High confidence
US 11,065,213	Amantadine Compositions and Preparations Thereof In force Term ends Aug 23, 2038 · High confidence	In force	Term ends Aug 23, 2038	High confidence

10 of 12 patents shown.

Pro members see all 12.

Pro members: see all 12 patents

Also on record, not counted in the 12: 2 patents in force now held by others · 21 patents ended · 27 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Adamas Pharma, LLC